Results 161 to 170 of about 77,108 (288)
Precision medicine in cutaneous melanoma—A comprehensive review
Journal of the European Academy of Dermatology and Venereology, EarlyView.Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley +1 more source
Profile of ipilimumab and its role in the treatment of metastatic melanoma
Drug Design, Development and Therapy, 2011 Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer.
Patel SP, Woodman SE
doaj
Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
Journal of the European Academy of Dermatology and Venereology, EarlyView.When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo +13 more
wiley +1 more source
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis
Journal of the European Academy of Dermatology and Venereology, EarlyView.Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel +27 more
wiley +1 more source
DEN Open, Volume 6, Issue 1, April 2026.Abstract Objective Recent advancements in genome analyses, including the BRAF gene and mismatch repair (MMR) gene/microsatellite instability (MSI), have revealed the biological diversity of colorectal cancer (CRC). BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have ...
Rika Omote +7 more
wiley +1 more source
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
Clinical, Cosmetic and Investigational Dermatology, 2013 Giulio Tosti, Emilia Cocorocchio, Elisabetta PennacchioliDivisione Melanomi e Sarcomi, Istituto Europeo di Oncologia, Milano, ItalyAbstract: Approaches aimed at enhancement of the tumor specific response have provided proof for the rationale of ...
Tosti G, Cocorocchio E, Pennacchioli E
doaj
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
New England Journal of Medicine, 2017 J. Weber +33 more
semanticscholar +1 more source
A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine
DEN Open, Volume 6, Issue 1, April 2026.ABSTRACT Enterocolitis is a common gastrointestinal manifestation of immune‐related adverse events (irAEs); however, only a few studies have reported on irAE enteritis with localized active inflammation in the small intestine. Here, we report the case of a 74‐year‐old man who developed diarrhea, abdominal pain, and oral intake difficulty and was ...
Ryo Morikawa +9 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 6, Page 1690-1702, 15 March 2026.What's new? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell +15 more
wiley +1 more source